| Rank |
Status |
Study |
| 1 |
Recruiting
|
Abuse Liability of Controlled-Release Oxycodone Formulations
| Condition: |
Substance-Related Disorders |
| Interventions: |
Drug: Apo-Oxycodone CR®; Drug: OxyNEO®; Drug: Oxycontin®; Drug: Placebo |
| Outcome Measures: |
Change from Baseline on Visual Analogue Scale for "Drug Liking" Over 8 Hours After Drug Administration; Change from Baseline on Visual Analogue Scale for "Drug High" Over 8 Hours After Drug Administration; Pupil Diameter; Cmax; Profile of Mood States (POMS); Psychomotor Performance; Visual Analogue Scale for "Any Drug Effects"; Visual Analogue Scale for "Good Effects"; Visual Analogue Scale for "Bad Effects"; Visual Analogue Scale for "Feel Sick"; Visual Analogue Scale for "Nausea"; Visual Analogue Scale for "Sleepy"; Visual Analogue Scale for "Dizzy"; Sedation; Euphoria; Dysphoric Changes; Psychotomimetic Changes; Somatic Disturbances; Sensory Disturbances; Tmax |
|
| 2 |
Recruiting
|
A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to Oxycontin in Korean Cancer Patients
| Condition: |
Cancer |
| Intervention: |
Drug: oxycodone and naloxone |
| Outcome Measures: |
Assess reduction of pain intensity; Efficacy parameters including long term safety and efficacy |
|
| 3 |
Recruiting
|
Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery
| Condition: |
Arthroplasty, Replacement, Hip |
| Interventions: |
Drug: Standard Care morphine hydrochloride; Drug: Oxycodone |
| Outcome Measures: |
Composite score of complications; Number of opioid boluses in the post-intervention surveillance room; Time to obtain a VAS score < 30/100 (from the first administration; minutes); Length of stay in the post-intervention surveillance room (minutes); Total dose of opioids during the first 24 hours (mg); Total number of opioid requestions (patient controlled analgesia = PCA); Total number of opioid requestions accepted / refused (PCA); Ramsay score; Presence / absence of an overdose of morphine/oxycodone (Ramsay score > 4); Presence / absence of an overdose of morphine/oxycodone (Ramsay score> 4); Presence/absence of complications; Patient satisfaction, VAS scale; Pain while at rest at while moving (Visual Analog Scale); DN4 score; Length of hospital stay (hours) |
|
| 4 |
Recruiting
|
Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain
| Condition: |
Postcraniotomy Pain |
| Interventions: |
Drug: Oxycodone; Drug: Codeine |
| Outcome Measures: |
To determine the difference in the mean pain VAS scores in the oxycodone and codeine groups at 24hr.; To look at the incidence of adverse events in the oxycodone and codeine groups. |
|
| 5 |
Recruiting
|
Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur
| Condition: |
Pain, Postoperative |
| Interventions: |
Drug: Buprenorphine; Drug: Oxycodone |
| Outcome Measures: |
Mobilization measured daily using Cumulated Ambulation Score.; Pain intensity measured daily on a verbal rating scale; Adverse effects; Opioid consumption.; Length of stay in Hospital |
|
| 6 |
Not yet recruiting
|
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
| Condition: |
Pediatric Surgical Patient |
| Intervention: |
Drug: oral oxycodone |
| Outcome Measure: |
Oxycodone, oxymorphone, noroxymorphone and noroxycodone serum levels |
|
| 7 |
Recruiting
|
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
| Condition: |
Pain |
| Intervention: |
Drug: Oxycodone HCl controlled-release tablets |
| Outcome Measures: |
The number of participants with adverse events as a measure of safety.; To characterize the efficacy and provide additional pharmacokinetics (PK) data of oxycodone hydrochloride controlled-release tablets |
|
| 8 |
Not yet recruiting
|
A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
| Condition: |
Healthy |
| Interventions: |
Drug: GL2907; Drug: Oxycontine CR 10mg |
| Outcome Measures: |
Cmax,ss; AUCτ; Tmax; t1/2; Vz/f; CL/F; Cmin,ss; Cave,ss; degree og fluctuation; swing; R |
|
| 9 |
Unknown †
|
Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
| Condition: |
Low Back Pain |
| Interventions: |
Drug: etoricoxib; Drug: oxycodone |
| Outcome Measures: |
Proportion of patients achieving a > 30% reduction in avg daily pain intensity at treatment week 4 (Visit 4).; Proportion of patients achieving a > 50% reduction in avg daily pain intensity at treatment week 5 (visit 4). |
|
| 10 |
Not yet recruiting
|
Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
| Condition: |
Healthy |
| Intervention: |
Drug: Oxycodone |
| Outcome Measures: |
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]; Maximum Observed Plasma Concentration (Cmax); Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast); Concentration at time 24 hours (C24); Time to Reach Maximum Observed Plasma Concentration (Tmax); Plasma Decay Half-Life (t1/2) |
|
| 11 |
Recruiting
|
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
| Condition: |
Pain |
| Intervention: |
Drug: Oxycodone |
| Outcome Measures: |
Cmax of Oxycodone Oral Solution.; Safety of Oxycodone Oral Solution in Pediatric Patients |
|
| 12 |
Recruiting
|
Targin Cancer Pain
| Conditions: |
Cancer; Pain |
| Interventions: |
Drug: Oxycodone/Naloxone; Drug: Oxycodone |
| Outcome Measures: |
BFI-Bowel Function Index; BPI-Brief Pain Index |
|
| 13 |
Recruiting
|
Targin for Non-cancer Pain
| Condition: |
Non Cancer Pain |
| Intervention: |
Drug: Oxycodone/naloxone prolonged release tablets |
| Outcome Measures: |
Bowel function index(BFI) 12 Weeks; Modified BPI-SF-Average Pain over the last 24 hours |
|
| 14 |
Unknown †
|
A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
| Condition: |
Post Tonsillectomy Pain |
| Interventions: |
Drug: 0,1 mg/kg of oxycodone; Drug: Morphine 0,1 mg/kg; Drug: Dexamethasone 0,5 mg/kg; Drug: NaCl 0,9% |
| Outcome Measures: |
The difference of needed rescue pain medication post operatively; differences in adverse effects |
|
| 15 |
Recruiting
|
An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
| Condition: |
Spinal Disorders Related Pain |
| Intervention: |
Drug: Oxycodone/Naloxone |
| Outcome Measures: |
24hr pain intensity score (Numeric rating score: 0 -10); EuroQol-5 Dimension(EQ-5D); Overall satisfaction of Physicians and subjects |
|
| 16 |
Not yet recruiting
|
A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
| Conditions: |
Postoperative Pain; Postoperative Nausea and Vomiting |
| Interventions: |
Drug: Targinact; Drug: Oxycodone; Procedure: Laparoscopic segmental colectomy |
| Outcome Measures: |
Prevalence of postoperative gut dysfunction; Pain control; Oral analgesia use; Pain scores |
|
| 17 |
Recruiting
|
Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury
| Condition: |
Pain |
| Interventions: |
Drug: Fentanyl; Drug: Oxycodone/acetaminophen; Drug: oxycodone/acetaminophen |
| Outcome Measures: |
Pain Level; Nausea level; Occurrence of adverse events |
|
| 18 |
Recruiting
|
Abuse Potential Study of PF-00345439
| Condition: |
Opioid Users |
| Interventions: |
Drug: Capsule; Drug: PF-00345439; Drug: oxycodone |
| Outcome Measures: |
Drug Liking: Peak Effect (Emax); High: Peak Effect (Emax); Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours; High: Area Under Effect Curve (AUE) From 0-2 Hours; Take Drug Again Effect at 24 Hours; Overall Drug Liking; Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour; Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour; Chewing Duration; Taste: Subjective Experience from Chewing; Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-2 Hours; Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-3 Hours; Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-12 Hours; Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours; Pupillometry: Area Under Effect Curve (AUE) From 0-3 Hours; Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours; High: Area Under Effect Curve (AUE) From 0-1 Hour; High: Area Under Effect Curve (AUE) From 0-3 Hours; High: Area Under Effect Curve (AUE) From 0-12 Hours; Good Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour; Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours; Good Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours; Good Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours; Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour; Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours; Bad Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours; Bad Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours; Feeling Sick: Area Under Effect Curve (AUE) From 0-1 Hour; Feeling Sick: Area Under Effect Curve (AUE) From 0-2 Hours; Feeling Sick: Area Under Effect Curve (AUE) From 0-3 Hours; Feeling Sick: Area Under Effect Curve (AUE) From 0-12 Hours; Nausea: Area Under Effect Curve (AUE) From 0-1 Hour; Nausea: Area Under Effect Curve (AUE) From 0-2 Hours; Nausea: Area Under Effect Curve (AUE) From 0-3 Hours; Nausea: Area Under Effect Curve (AUE) From 0-12 Hours; Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour; Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours; Sleepy: Area Under Effect Curve (AUE) From 0-3 Hours; Sleepy: Area Under Effect Curve (AUE) From 0-12 Hour; Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour; Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours; Dizzy: Area Under Effect Curve (AUE) From 0-3 Hours; Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours; Bad Effects: Peak Effect (Emax); Nausea: Peak Effect (Emax); Feel Sick: Peak Effect (Emax); Sleepy: Peak Effect (Emax); Dizzy: Peak Effect (Emax); Pupillometry: Peak Effect (Emax); Good Drug Effects: Peak Effect (Emax); Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour; Drug Liking: Area Under Effect Curve (AUE) From 0-3 Hours; Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours; Drug Liking: Time to Maximum (Peak) Effect (TEmax); High: Time to Maximum (Peak) Effect (TEmax); Any Drug Effects: Time to Maximum (Peak) Effect (TEmax); Good Drug Effects: Time to Maximum (Peak) Effect (TEmax); Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax); Feel Sick: Time to Maximum (Peak) Effect (TEmax); Nausea: Time to Maximum (Peak) Effect (TEmax); Sleepy: Time to Maximum (Peak) Effect (TEmax); Dizzy: Time to Maximum (Peak) Effect (TEmax); Pupillometry: Time to Maximum (Peak) Effect (TEmax); Any Drug Effects: Peak Effect (Emax); Texture: Subjective Experience from Chewing; Maximum Observed Plasma Concentration (Cmax); Time to Reach Maximum Observed Plasma Concentration (Tmax); Area under the curve (AUC); Systemic Clearance (CL); volume of distribution (Vd); Half-Life (t1/2) |
|
| 19 |
Recruiting
|
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
| Condition: |
Opioid Abuse |
| Intervention: |
Drug: pioglitazone |
| Outcome Measures: |
Subjective ratings of drug, mood, and physiological effects; Analgesic responses using the cold pressor test |
|
| 20 |
Recruiting
|
RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
| Conditions: |
Cancer; Cancer Pain |
| Interventions: |
Drug: Morphine; Drug: Fentanyl; Drug: Buprenorphine; Drug: Oxycodone |
| Outcome Measures: |
Proportion of Non-Responder (NR) patients; Proportion of full-responder |
|
